Replies to post #3899 on Biotech Values

[DewDiligence]

>> Seeing the barrage of PR, makes me wonder. <<

Let’s analyze that. The timing of today’s PR was dictated by the FDA. The timing of the PR for the start of the “208” combo trial was presumably fixed by the actual opening of that trial for enrollment. That leaves the two PR’s about the SBIR grants; these GENR could conceivably have sat on for a while to exploit the timing; e.g. GENR may have issued the Trodusquemine PR in concert with MRK’s obesity deal with NSTK.

Overall, the evidence for a financing based on this sequence of PR’s is pretty weak, IMHO.

[DewDiligence]

>> Nice job on the trade. <<

Thanks. With the profit from this latest trade, the average cost basis on my entire GENR holding is now less than zero for the first time.